(FRE) Fresenius SE & Co. KGaA - Overview
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE0005785604
Stock:
Total Rating 56
Risk 80
Buy Signal -0.26
| Risk 5d forecast | |
|---|---|
| Volatility | 22.3% |
| Relative Tail Risk | -4.57% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.19 |
| Alpha | 28.42 |
| Character TTM | |
|---|---|
| Beta | 0.235 |
| Beta Downside | 0.339 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.08% |
| CAGR/Max DD | 1.44 |
EPS (Earnings per Share)
Revenue
Description: FRE Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 1.14b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -2.90 > 1.0 |
| NWC/Revenue: 11.17% < 20% (prev 13.28%; Δ -2.11% < -1%) |
| CFO/TA 0.05 > 3% & CFO 2.19b > Net Income 1.14b |
| Net Debt (11.18b) to EBITDA (3.34b): 3.34 < 3 |
| Current Ratio: 1.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (563.2m) vs 12m ago 0.21% < -2% |
| Gross Margin: 24.99% > 18% (prev 0.24%; Δ 2475 % > 0.5%) |
| Asset Turnover: 52.69% > 50% (prev 52.42%; Δ 0.27% > 0%) |
| Interest Coverage Ratio: 6.42 > 6 (EBITDA TTM 3.34b / Interest Expense TTM 344.0m) |
Altman Z'' 3.65
| A: 0.06 (Total Current Assets 12.06b - Total Current Liabilities 9.56b) / Total Assets 42.46b |
| B: 0.44 (Retained Earnings 18.60b / Total Assets 42.46b) |
| C: 0.05 (EBIT TTM 2.21b / Avg Total Assets 42.41b) |
| D: 1.42 (Book Value of Equity 32.91b / Total Liabilities 23.19b) |
| Altman-Z'' Score: 3.65 = AA |
Beneish M -2.73
| DSRI: 1.46 (Receivables 5.60b/3.82b, Revenue 22.35b/22.21b) |
| GMI: 0.95 (GM 24.99% / 23.82%) |
| AQI: 0.97 (AQ_t 0.49 / AQ_t-1 0.51) |
| SGI: 1.01 (Revenue 22.35b / 22.21b) |
| TATA: -0.02 (NI 1.14b - CFO 2.19b) / TA 42.46b) |
| Beneish M-Score: -2.73 (Cap -4..+1) = A |
What is the price of FRE shares?
As of March 02, 2026, the stock is trading at EUR 50.90 with a total of 1,057,637 shares traded.
Over the past week, the price has changed by -1.59%, over one month by +6.13%, over three months by +9.77% and over the past year by +32.83%.
Over the past week, the price has changed by -1.59%, over one month by +6.13%, over three months by +9.77% and over the past year by +32.83%.
Is FRE a buy, sell or hold?
Fresenius SE & Co. KGaA has no consensus analysts rating.
What are the forecasts/targets for the FRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 55.7 | 9.4% |
| Analysts Target Price | - | - |
FRE Fundamental Data Overview March 02, 2026
Market Cap USD = 33.81b (28.67b EUR * 1.1794 EUR.USD)
P/E Trailing = 24.8293
P/E Forward = 13.8122
P/S = 1.2773
P/B = 1.5395
P/EG = 0.3848
Revenue TTM = 22.35b EUR
EBIT TTM = 2.21b EUR
EBITDA TTM = 3.34b EUR
Long Term Debt = 9.53b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.74b EUR (from shortTermDebt, last quarter)
Debt = 13.54b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.18b EUR (from netDebt column, last quarter)
Enterprise Value = 39.84b EUR (28.67b + Debt 13.54b - CCE 2.36b)
Interest Coverage Ratio = 6.42 (Ebit TTM 2.21b / Interest Expense TTM 344.0m)
EV/FCF = 32.93x (Enterprise Value 39.84b / FCF TTM 1.21b)
FCF Yield = 3.04% (FCF TTM 1.21b / Enterprise Value 39.84b)
FCF Margin = 5.41% (FCF TTM 1.21b / Revenue TTM 22.35b)
Net Margin = 5.11% (Net Income TTM 1.14b / Revenue TTM 22.35b)
Gross Margin = 24.99% ((Revenue TTM 22.35b - Cost of Revenue TTM 16.76b) / Revenue TTM)
Gross Margin QoQ = 23.70% (prev 26.12%)
Tobins Q-Ratio = 0.94 (Enterprise Value 39.84b / Total Assets 42.46b)
Interest Expense / Debt = 0.60% (Interest Expense 81.0m / Debt 13.54b)
Taxrate = 24.22% (116.0m / 479.0m)
NOPAT = 1.67b (EBIT 2.21b * (1 - 24.22%))
Current Ratio = 1.26 (Total Current Assets 12.06b / Total Current Liabilities 9.56b)
Debt / Equity = 0.73 (Debt 13.54b / totalStockholderEquity, last quarter 18.62b)
Debt / EBITDA = 3.34 (Net Debt 11.18b / EBITDA 3.34b)
Debt / FCF = 9.24 (Net Debt 11.18b / FCF TTM 1.21b)
Total Stockholder Equity = 18.96b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.69% (Net Income 1.14b / Total Assets 42.46b)
RoE = 6.03% (Net Income TTM 1.14b / Total Stockholder Equity 18.96b)
RoCE = 7.76% (EBIT 2.21b / Capital Employed (Equity 18.96b + L.T.Debt 9.53b))
RoIC = 5.41% (NOPAT 1.67b / Invested Capital 30.95b)
WACC = 4.75% (E(28.67b)/V(42.21b) * Re(6.78%) + D(13.54b)/V(42.21b) * Rd(0.60%) * (1-Tc(0.24)))
Discount Rate = 6.78% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 85.14% ; FCFF base≈1.70b ; Y1≈1.52b ; Y5≈1.29b
[DCF] Fair Price = 49.24 (EV 38.91b - Net Debt 11.18b = Equity 27.73b / Shares 563.2m; r=5.90% [WACC]; 5y FCF grow -13.08% → 2.90% )
EPS Correlation: 43.22 | EPS CAGR: 4.05% | SUE: 0.64 | # QB: 0
Revenue Correlation: -84.91 | Revenue CAGR: -14.72% | SUE: -0.10 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.96 | Chg7d=+0.961 | Chg30d=+0.961 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-12-31): EPS=3.75 | Chg7d=+0.030 | Chg30d=+0.064 | Revisions Net=-9 | Growth EPS=+6.0% | Growth Revenue=+3.2%
EPS next Year (2027-12-31): EPS=4.08 | Chg7d=-0.004 | Chg30d=+0.048 | Revisions Net=-8 | Growth EPS=+8.9% | Growth Revenue=+5.1%
[Analyst] Revisions Ratio: -1.00 (0 Up / 9 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.9% (Discount Rate 7.9% - Earnings Yield 4.0%)
[Growth] Growth Spread = +0.7% (Analyst 4.6% - Implied 3.9%)
P/E Trailing = 24.8293
P/E Forward = 13.8122
P/S = 1.2773
P/B = 1.5395
P/EG = 0.3848
Revenue TTM = 22.35b EUR
EBIT TTM = 2.21b EUR
EBITDA TTM = 3.34b EUR
Long Term Debt = 9.53b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.74b EUR (from shortTermDebt, last quarter)
Debt = 13.54b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.18b EUR (from netDebt column, last quarter)
Enterprise Value = 39.84b EUR (28.67b + Debt 13.54b - CCE 2.36b)
Interest Coverage Ratio = 6.42 (Ebit TTM 2.21b / Interest Expense TTM 344.0m)
EV/FCF = 32.93x (Enterprise Value 39.84b / FCF TTM 1.21b)
FCF Yield = 3.04% (FCF TTM 1.21b / Enterprise Value 39.84b)
FCF Margin = 5.41% (FCF TTM 1.21b / Revenue TTM 22.35b)
Net Margin = 5.11% (Net Income TTM 1.14b / Revenue TTM 22.35b)
Gross Margin = 24.99% ((Revenue TTM 22.35b - Cost of Revenue TTM 16.76b) / Revenue TTM)
Gross Margin QoQ = 23.70% (prev 26.12%)
Tobins Q-Ratio = 0.94 (Enterprise Value 39.84b / Total Assets 42.46b)
Interest Expense / Debt = 0.60% (Interest Expense 81.0m / Debt 13.54b)
Taxrate = 24.22% (116.0m / 479.0m)
NOPAT = 1.67b (EBIT 2.21b * (1 - 24.22%))
Current Ratio = 1.26 (Total Current Assets 12.06b / Total Current Liabilities 9.56b)
Debt / Equity = 0.73 (Debt 13.54b / totalStockholderEquity, last quarter 18.62b)
Debt / EBITDA = 3.34 (Net Debt 11.18b / EBITDA 3.34b)
Debt / FCF = 9.24 (Net Debt 11.18b / FCF TTM 1.21b)
Total Stockholder Equity = 18.96b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.69% (Net Income 1.14b / Total Assets 42.46b)
RoE = 6.03% (Net Income TTM 1.14b / Total Stockholder Equity 18.96b)
RoCE = 7.76% (EBIT 2.21b / Capital Employed (Equity 18.96b + L.T.Debt 9.53b))
RoIC = 5.41% (NOPAT 1.67b / Invested Capital 30.95b)
WACC = 4.75% (E(28.67b)/V(42.21b) * Re(6.78%) + D(13.54b)/V(42.21b) * Rd(0.60%) * (1-Tc(0.24)))
Discount Rate = 6.78% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 85.14% ; FCFF base≈1.70b ; Y1≈1.52b ; Y5≈1.29b
[DCF] Fair Price = 49.24 (EV 38.91b - Net Debt 11.18b = Equity 27.73b / Shares 563.2m; r=5.90% [WACC]; 5y FCF grow -13.08% → 2.90% )
EPS Correlation: 43.22 | EPS CAGR: 4.05% | SUE: 0.64 | # QB: 0
Revenue Correlation: -84.91 | Revenue CAGR: -14.72% | SUE: -0.10 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.96 | Chg7d=+0.961 | Chg30d=+0.961 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-12-31): EPS=3.75 | Chg7d=+0.030 | Chg30d=+0.064 | Revisions Net=-9 | Growth EPS=+6.0% | Growth Revenue=+3.2%
EPS next Year (2027-12-31): EPS=4.08 | Chg7d=-0.004 | Chg30d=+0.048 | Revisions Net=-8 | Growth EPS=+8.9% | Growth Revenue=+5.1%
[Analyst] Revisions Ratio: -1.00 (0 Up / 9 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.9% (Discount Rate 7.9% - Earnings Yield 4.0%)
[Growth] Growth Spread = +0.7% (Analyst 4.6% - Implied 3.9%)